Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System.
Animals
Aquaporin 4
/ immunology
Autoantibodies
/ blood
Case-Control Studies
Cell Differentiation
Central Nervous System
/ immunology
Cerebellum
/ immunology
Female
Humans
Immunoglobulin G
/ immunology
Male
Mice, Inbred BALB C
Middle Aged
Neuromyelitis Optica
/ blood
Oligodendrocyte Precursor Cells
/ immunology
AQP4–IgG
NMOSD
neural stem cells
neurogenesis
neuromyelitis optica
precursor cells
remyelination
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 May 2021
14 May 2021
Historique:
received:
25
03
2021
revised:
11
05
2021
accepted:
11
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
11
6
2021
Statut:
epublish
Résumé
AQP4 (aquaporin-4)-immunoglobulin G (IgG)-mediated neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease that affects the central nervous system, particularly the spinal cord and optic nerve; remyelination capacity in neuromyelitis optica is yet to be determined, as is the role of AQP4-IgG in cell differentiation. We included three groups-a group of patients with AQP4-IgG-positive neuromyelitis optica, a healthy group, and a sham group. We analyzed differentiation capacity in cultures of neurospheres from the subventricular zone of mice by adding serum at two different times: early and advanced stages of differentiation. We also analyzed differentiation into different cell lines. The effect of sera from patients with NMOSD on precursor cells differs according to the degree of differentiation, and probably affects oligodendrocyte progenitor cells from NG2 cells to a lesser extent than cells from the subventricular zone; however, the resulting oligodendrocytes may be compromised in terms of maturation and possibly limited in their ability to generate myelin. Furthermore, these cells decrease in number with age. It is very unlikely that the use of drugs favoring the migration and differentiation of oligodendrocyte progenitor cells in multiple sclerosis would be effective in the context of neuromyelitis optica, but cell therapy with oligodendrocyte progenitor cells seems to be a potential alternative.
Identifiants
pubmed: 34068922
pii: ijms22105192
doi: 10.3390/ijms22105192
pmc: PMC8155872
pii:
doi:
Substances chimiques
AQP4 protein, human
0
Aquaporin 4
0
Autoantibodies
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Neurol. 2020 Jun 26;11:501
pubmed: 32670177
Cancer Res. 2019 May 1;79(9):2182-2194
pubmed: 30877104
Neuroscientist. 2013 Apr;19(2):195-207
pubmed: 22645111
Front Cell Neurosci. 2016 May 10;10:119
pubmed: 27242432
Bioengineering (Basel). 2021 Feb 23;8(2):
pubmed: 33672148
Int J Mol Sci. 2012 Oct 11;13(10):12970-93
pubmed: 23202933
Brain. 2010 Sep;133(9):2578-91
pubmed: 20688809
Front Neurol. 2020 Jul 07;11:638
pubmed: 32733364
Neuropathology. 2010 Aug;30(4):427-33
pubmed: 19925565
J Cell Sci. 2008 Dec 15;121(Pt 24):4029-36
pubmed: 19033383
J Biol Chem. 2011 Mar 18;286(11):9216-24
pubmed: 21212277
Int J Mol Sci. 2016 Aug 10;17(8):
pubmed: 27517922
Front Neurol. 2017 Jun 06;8:255
pubmed: 28634469
J Biomol Screen. 2016 Jul;21(6):567-78
pubmed: 26962874
Int J Mol Sci. 2019 Mar 29;20(7):
pubmed: 30934923
Neurochem Int. 2010 Apr;56(5):651-4
pubmed: 20138100
Glia. 2006 Jan 15;53(2):167-81
pubmed: 16206164
Ann Neurol. 2009 Nov;66(5):617-29
pubmed: 19938104
Mult Scler Relat Disord. 2019 Jan;27:412-418
pubmed: 30530071
Front Bioeng Biotechnol. 2020 May 05;8:389
pubmed: 32432095
Med Clin (Barc). 2017 Apr 21;148(8):377-380
pubmed: 27923464
J Cereb Blood Flow Metab. 2002 Apr;22(4):367-78
pubmed: 11919508
Exp Neurol. 2003 Dec;184(2):955-63
pubmed: 14769388
Cell. 2020 May 14;181(4):784-799.e19
pubmed: 32413299
Glia. 2009 Oct;57(13):1363-73
pubmed: 19229993
PLoS One. 2013 Aug 22;8(8):e72919
pubmed: 23991165
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Acta Neuropathol. 2014 Apr;127(4):523-38
pubmed: 24292009
Biol Cell. 2006 Feb;98(2):89-94
pubmed: 15907198
Sci Rep. 2019 Dec 30;9(1):20369
pubmed: 31889130
Differentiation. 2016 Apr-Jun;91(4-5):28-41
pubmed: 27016251
Trends Neurosci. 2015 Mar;38(3):145-57
pubmed: 25579391
Neuroreport. 2016 Aug 17;27(12):894-900
pubmed: 27362437
Brain. 2020 Sep 1;143(9):2721-2732
pubmed: 32889550
CNS Neurosci Ther. 2014 May;20(5):385-90
pubmed: 24712483
Neuroimmunomodulation. 2016;23(5-6):309-317
pubmed: 28427055
Cell Mol Life Sci. 2006 Jun;63(12):1386-92
pubmed: 16715408
Nat Rev Drug Discov. 2014 Apr;13(4):259-77
pubmed: 24625825
Brain Pathol. 2013 Nov;23(6):684-95
pubmed: 24118484
Curr Opin Cell Biol. 2014 Dec;31:23-8
pubmed: 25033469
Neuropsychopharmacology. 2009 Apr;34(5):1263-76
pubmed: 18923397
Biochim Biophys Acta. 2015 Dec;1850(12):2410-21
pubmed: 26365508
Ann Clin Transl Neurol. 2019 Oct;6(10):2079-2087
pubmed: 31568704
Lancet Neurol. 2012 Jun;11(6):535-44
pubmed: 22608667
J Neuroophthalmol. 2017 Sep;37(3):291-299
pubmed: 28410278
Glia. 2018 Dec;66(12):2575-2588
pubmed: 30240044
Biochim Biophys Acta Biomembr. 2021 May 1;1863(5):183573
pubmed: 33561476
J Clin Lab Anal. 2012 May;26(3):184-9
pubmed: 22628234
Curr Treat Options Neurol. 2016 Jan;18(1):2
pubmed: 26705758
Clin Exp Nephrol. 2009 Apr;13(2):107-117
pubmed: 19085041
Clin Exp Neuroimmunol. 2014 Oct;5(3):290-303
pubmed: 27840658
Acta Neurol Belg. 2016 Jun;116(2):127-34
pubmed: 26259614
Front Bioeng Biotechnol. 2020 Sep 28;8:573775
pubmed: 33117784
J Neuroinflammation. 2016 Dec 1;13(1):301
pubmed: 27905992
Acta Neuropathol Commun. 2016 Apr 26;4(1):42
pubmed: 27117475
Eur J Neurosci. 2017 Nov;46(9):2542-2547
pubmed: 28925524
Acta Neuropathol. 2013 Jun;125(6):815-27
pubmed: 23579868
Ann Neurol. 2012 Sep;72(3):385-94
pubmed: 23034911